ClinicalTrials.gg
Not yet recruitingNCT07502781ReCoRDBCNUpdated Nov 9, 2026

Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants

An interventional study of Cord Blood Red Blood Cells and Standard Adult Donor Red Blood Cells in Extremely Premature Infant, Anemia Neonatal and Blood Transfusion, sponsored by Hospital Clinic of Barcelona. Not yet recruiting at 1 site in Spain. Open to participants aged 23 Weeks to 28 Weeks. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Prevention

How we know

Updated Nov 9, 2026Enrollment updatedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
23 Weeks to 28 Weeks
Sex
All
01

Study summary

Anemia is a condition in which there are not enough red blood cells to carry oxygen throughout the body. It is very common in extremely preterm infants (born before 28 weeks of pregnancy), and many of these babies require red blood cell transfusions during their hospital stay.

Currently, transfusions are given using red blood cells donated by adults. An alternative option is to use red blood cells collected from umbilical cord blood, which may be more similar to a newborn's own blood. This approach has been used in some neonatal units with encouraging results and no reported safety concerns.

This study aims to determine whether transfusion with umbilical cord blood improves clinical outcomes and reduces potential side effects compared to standard adult donor blood transfusion in extremely preterm infants. We hypothesize that umbilical cord blood transfusion will be at least as safe as adult donor blood and may provide clinical benefits.

Infants admitted to neonatal units in Catalonia will participate. If parents agree, their baby will be randomly assigned to receive either compatible umbilical cord blood or compatible adult donor blood if a transfusion becomes necessary. Babies will only receive a transfusion if they clinically need one. If cord blood is not available at the time of transfusion, the baby will receive compatible adult donor blood regardless of the assigned group.

To evaluate the response to treatment, small blood samples will be collected at birth, at one month of life, and 24 hours after any transfusion. These samples are taken at the same times as routine blood tests, so participation does not require additional needle sticks. The amount of blood collected is minimal (about 0.2 mL per sample).

Participation will continue until the baby reaches 40 weeks of postmenstrual age.

Read the detailed description

Neonatal anemia is a common condition in extremely preterm infants (born before 28 weeks of gestation) and is associated with significant health risks. Despite the implementation of evidence-based strategies to reduce anemia, such as delayed umbilical cord clamping and cord milking, many extremely preterm infants still require red blood cell transfusions during the first weeks of life due to a multifactorial decline in hemoglobin levels.

Currently, red blood cell transfusions for these infants use blood from adult donors. Transfusion of adult donor blood has been associated with complications linked to fluctuations in tissue oxygen levels, including retinopathy of prematurity and bronchopulmonary dysplasia. One key factor contributing to these complications is the lower proportion of fetal hemoglobin (HbF) in adult donor blood compared to the infant's natural blood. HbF has a higher affinity for oxygen and releases oxygen more slowly, whereas adult hemoglobin (HbA) delivers oxygen more rapidly to tissues, increasing the risk of oxygen toxicity. Additionally, adult donor blood may contain trace amounts of heavy metals, which could potentially affect extremely preterm infants, although this has not been formally studied.

Red blood cell concentrates derived from umbilical cord blood (CB-RBC) provide an alternative that is closer to the infant's own blood composition. CB-RBC transfusions contain higher levels of HbF, which may reduce tissue oxygen stress. Pilot studies in our center have shown that CB-RBC transfusions are feasible, safe, and effective. In one preliminary study, ten extremely preterm infants (\<28 weeks gestation) received a total of 23 CB-RBC transfusions without adverse reactions, indicating that this approach is safe in clinical practice. However, medium- and long-term benefits of CB-RBC transfusions remain unclear.

Recent research shows that higher HbF levels are inversely correlated with morbidities related to tissue hyperoxygenation, such as retinopathy of prematurity. Studies in Italy, including those by Teofili et al., have shown encouraging trends toward reducing severe retinopathy, although small sample sizes prevented statistical significance. These findings support the need for a larger randomized multicenter trial to evaluate clinical outcomes more conclusively.

This study is a randomized multicenter clinical trial coordinated among all major level 3A and 3B public neonatal units in the Barcelona area, with unanimous support from participating units. Eligible infants will be randomly assigned to receive either CB-RBC transfusions or standard adult donor red blood cell transfusions if a transfusion is clinically indicated. Transfusions will only be performed when medically necessary. If cord blood is not available at the time of transfusion, compatible adult donor blood will be used regardless of assigned group.

To assess the effects of transfusion, small blood samples will be collected at birth, at one month of age, and 24 hours after any transfusion. Blood collection follows routine clinical practice, and volumes are minimal (\~0.2 mL per sample). All procedures are designed to minimize risk and discomfort for participants.

Study Hypothesis: We hypothesize that transfusion with cord blood red blood cell concentrates will reduce retinopathy of prematurity, compared to transfusions with standard adult donor red blood cells.

The results of this study aim to provide strong evidence regarding the clinical benefits of CB-RBC transfusions in extremely preterm infants, including the potential to reduce transfusion-related complications and improve outcomes. If successful, this approach could be implemented more widely to enhance neonatal care for this vulnerable population

02

Conditions studied

  • Extremely Premature Infant
  • Anemia Neonatal
  • Blood Transfusion
  • Umbilical Cord Blood
  • Fetal Hemoglobin
  • Bronchopulmonary Dysplasia (BPD)
  • Retinopathy of Prematurity (ROP)
  • Death; Neonatal
  • Intensive Care Units, Neonatal

Keywords

  • Cord blood red blod cell transfusion
  • Umbilical cord blood transfusion
  • Extremely preterm infants
  • Neonatal anemia
  • Fetal hemoglobin
  • Adult donor red blood cells
  • Bronchopulmonary dysplasia
  • Retinopathy of prematurity
  • Oxygen delivery
  • Days requiring oxygen supplementation
03

In context

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

This study's planned enrollment of 280 is above the median of 40 across 209 interventional studies indexed under beta-Thalassemia.

Browse beta-Thalassemia studies →

Lead sponsor

Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
23 Weeks to 28 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed obtained from parents or legal guardians.
  • Gestational age at birth \< 28 weeks or birth weight \< 1000 g.
  • Admission to one of the participating neonatal intensive care units (NICUs) in the Barcelona area.

Exclusion criteria

Exclusion Criteria:

  • Prior red blood cell transfusion during the fetal or neonatal period.
  • Maternal-fetal immunization (e.g., isoimmunization).
  • Fetal hydrops.
  • Major congenital malformations.
  • Congenital infections.
  • Immediate need for blood before randomization (e.g., hemorrhagic shock, consumptive coagulopathy).
  • Participation in another clinical trial that could interfere with the primary outcome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Cord Blood-Derived Red Blood Cell Transfusion

    Extremely preterm infants randomized to this arm will receive red blood cell transfusions derived from umbilical cord blood (CB-RBC) when a transfusion is clinically indicated according to standard neonatal guidelines. If compatible cord blood units are not available at the time of transfusion, standard adult donor red blood cells may be used.

    Biological: Cord Blood Red Blood Cells

  • Active comparator
    Adult Donor Red Blood Cell Transfusion

    Extremely preterm infants randomized to this arm will receive standard adult donor red blood cell transfusions when a transfusion is clinically indicated according to standard neonatal guidelines.

    Biological: Standard Adult Donor Red Blood Cells

Interventions

  • BiologicalCord Blood Red Blood Cells

    Neonates receive transfusions of red blood cells derived from allogeneic umbilical cord blood, ABO/RhD compatible. Dosage: 15-20 mL/kg per transfusion, administered according to clinical indication and availability. If cord blood is not available at the time of transfusion, adult donor red blood cells (CH-SA) are given instead. Monitoring: Vital signs, complete blood count, hematocrit and fetal hemoglobin (HbF) are recorded before and after transfusion.

    Also known as: CH-SCU

  • BiologicalStandard Adult Donor Red Blood Cells

    Neonates receive transfusions of red blood cells derived from adult donors, ABO/RhD compatible. Dosage: 15-20 mL/kg per transfusion, administered according to clinical indication and the protocol of each neonatal unit. Transfusions are performed only when medically necessary. Monitoring: Vital signs, complete blood count, hematocrit and fetal hemoglobin (HbF) are recorded before and after transfusion.

    Also known as: CH-SA

06

What researchers measure

Primary outcomes

  1. Retinopathy of prematurity stage 2 or more

    The primary outcome is to evaluate the incidence of Retinopathy of prematurity (stage 2 or more) diagnosed according to the International Classification of Retinopathy of Prematurity, assessed by ophthalmologists blinded to group allocation using ophthalmoscopy and the Catalonia Ophthalmic Telemedicine Network (RTOC).

    Time frame: From birth until 40 weeks postmenstrual age.

Secondary outcomes

  1. Bronchopulmonary dysplasia (BPD, any grade)

    To evaluate the incidence of Bronchopulmonary dysplasia (BPD, any grade) defined as the need for oxygen therapy or any respiratory support at 36 weeks postmenstrual age (PMA). Classified according to Jensen et al. (2019), assessed at 36 weeks PMA.

    Time frame: From birth until 36 weeks postmenstrual age or hospital discharge, whichever occurs first.

  2. Fetal hemoglobin (HbF) threshold at one month associated with clinical outcomes

    To evaluate the fetal haemoglobin (HbF) percentage cutoff at one month of life that best correlates with a reduction in the composite outcome of retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), or death, as well as with each outcome individually. Due to limited availability of cord blood units (CB-RBC), some infants assigned to this group may receive adult donor red blood cells. This analysis aims to identify protective or critical HbF thresholds for the development of ROP and BPD.

    Time frame: At one month of life.

  3. Oxygen-free days within 90 days post-randomization

    To evaluate the impact of cord blood-derived red blood cell transfusion (CB-RBC) versus standard adult donor red blood cell transfusion (AD-RBC) on intermediate outcomes, specifically the number of oxygen-free days during the 90 days following randomization.

    Time frame: Up to 90 days after randomization.

Other outcomes

  1. Hematologic parameters post-transfusion (1)

    Assessment of transfusion efficacy via changes in total hematocrit.An increment in hematocrit by 12 ± 5 points 24 hours after the transfusion will be considered effective. This analysis aims to demonstrate non-inferiority of CB-RBC vs AD-RBC.

    Time frame: Pre-transfusion, 24 hours post-transfusion, and at 1 month of age

  2. Hematologic parameters post-transfusion (2)

    Assessment of transfusion efficacy via changes in total hemoglobin. An increment in total hemoglobin by 4 ± 2 g / dL 24 hours after the transfusion will be considered effective. Samples will be analysed by microhematocrit method. This analysis aims to demonstrate non-inferiority of CB-RBC vs AD-RBC.

    Time frame: Pre-transfusion, 24 hours post-transfusion, and at 1 month of age

  3. Fetal hemoglobin (HbF) percentage evolution

    Measure changes in HbF percentage over time (at birth, pre- and post-transfusion, and at 1 month), evaluating its association with intermediate and clinical outcomes.

    Time frame: At birth, 24 hours post-transfusion, and 1 month of age

  4. Red blood cell transfusion requirements (1)

    Total volume of transfusions (mililiters) received until 36 weeks PMA or hospital discharge, comparing CB-RBC vs AD-RBC.

    Time frame: From birth until 36 weeks PMA or hospital discharge

  5. Red blood cell transfusion requirements (2)

    Total number of transfusions received until 36 weeks PMA or hospital discharge, comparing CB-RBC vs AD-RBC.

    Time frame: From birth until 36 weeks PMA or hospital discharge

  6. Bone marrow regeneration parameters

    Reticulocyte counts will be measured at 1 month of life as an indicator of marrow regeneration

    Time frame: 1 month of life

  7. Iron metabolism values

    Ferritin levels at 1 month of life will be measured as an indicator of iron metabolism

    Time frame: 1 month of life

07

Study locations

1 site
  • Hospital Clínic de Barcelona - Maternitat
    Barcelona, 08028, Spain
    • Miguel Maria Alsina Casanova, MD · Contactmmalsina@clinic.cat · +34932275600
    • Miguel Ramón Jimenez, MD · Principal investigator
    • Fátima Camba Longueira, MD · Principal investigator
    • María José García Borau, MD · Principal investigator
    • Marta Ocaña Rico, MD · Principal investigator
    • Mònica Domingo Puiggròs, MD · Principal investigator
08

References and documents

Publications

  • Torrejon-Rodriguez L, Pinilla-Gonzalez A, Lara Canton I, Albiach-Delgado A, Cascant-Vilaplana MM, Cernada M, Kuligowski J, Solves Alcaina MP, Gomez I, Vento M, Aguar Carrascosa M. Effect of autologous umbilical cord blood transfusion in the development of retinopathy of prematurity: randomized clinical trial - study protocol. Front Pediatr. 2023 Oct 12;11:1269797. doi: 10.3389/fped.2023.1269797. eCollection 2023. PubMed 37900679 ↗
  • Teofili L, Papacci P, Dani C, Cresi F, Remaschi G, Pellegrino C, Bianchi M, Ansaldi G, Campagnoli MF, Vania B, Lepore D, Franco FGS, Fabbri M, de Vera d' Aragona RP, Molisso A, Beccastrini E, Dragonetti A, Orazi L, Pasciuto T, Mozzetta I, Baldascino A, Locatelli E, Valentini CG, Giannantonio C, Carducci B, Gabbriellini S, Albiani R, Ciabatti E, Nicolotti N, Baroni S, Mazzoni A, Besso FG, Serrao F, Purcaro V, Coscia A, Pizzolo R, Raffaeli G, Villa S, Mondello I, Trimarchi A, Beccia F, Ghirardello S, Vento G. Cord blood transfusions in extremely low gestational age neonates to reduce severe retinopathy of prematurity: results of a prespecified interim analysis of the randomized BORN trial. Ital J Pediatr. 2024 Aug 7;50(1):142. doi: 10.1186/s13052-024-01714-w. PubMed 39113069 ↗
  • Teofili L, Papacci P, Orlando N, Bianchi M, Molisso A, Purcaro V, Valentini CG, Giannantonio C, Serrao F, Chiusolo P, Nicolotti N, Pellegrino C, Carducci B, Vento G, De Stefano V. Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB-TrIP study. Br J Haematol. 2020 Oct;191(2):263-268. doi: 10.1111/bjh.16851. Epub 2020 Jun 8. PubMed 32510635 ↗
  • Gonzalez EG, Casanova MA, Samarkanova D, Aldecoa-Bilbao V, Teresa-Palacio M, Busquets EF, Figueras-Aloy J, Salvia-Roiges M, Querol S. Feasibility of umbilical cord blood as a source of red blood cell transfusion in preterm infants. Blood Transfus. 2021 Nov;19(6):510-517. doi: 10.2450/2020.0169-20. Epub 2020 Dec 18. PubMed 33370228 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Of 29 interventional studies with no phase under beta-Thalassemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 31, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
176→280
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Composite outcome of bronchopulmonary dysplasia, retinopathy of prematurity, or death in extremely prematursNow Retinopathy of prematurity stage 2 or moreTime frame: From birth until 36 weeks postmenstrual age or hospital discharge (whichever occurs first). → From birth until 40 weeks postmenstrual age.
Nov 9, 2026
Secondary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedBronchopulmonary dysplasia (BPD, any grade)Time frame: From birth until 36 weeks postmenstrual age or hospital discharge, whichever occurs first.
  • Removedother outcomeTissue oxygenation measured by NIRSTime frame: From transfusion initiation until 24 hours post-transfusion
  • Removedother outcomeMarkers of oxidative stressTime frame: At birth, post-transfusion, and 1 month of age
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Enrollment 176→280
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Composite outcome of bronchopulmonary dysplasia, retinopathy of prematurity, or death in extremely prematursNow Retinopathy of prematurity stage 2 or moreTime frame: From birth until 36 weeks postmenstrual age or hospital discharge (whichever occurs first). → From birth until 40 weeks postmenstrual age.
    Secondary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedBronchopulmonary dysplasia (BPD, any grade)Time frame: From birth until 36 weeks postmenstrual age or hospital discharge, whichever occurs first.
    • Removedother outcomeTissue oxygenation measured by NIRSTime frame: From transfusion initiation until 24 hours post-transfusion
    • Removedother outcomeMarkers of oxidative stressTime frame: At birth, post-transfusion, and 1 month of age
    + 5 other changes: identifiers, verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07502781
Collaborators
Hospital Sant Joan de Deu, Hospital de la Santa creu i Sant Pau - Barcelona, Hospital Vall d'Hebron, Germans Trias i Pujol Hospital, Parc Taulí Hospital Universitari
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Miguel Maria Alsina Casanova, MD
Contact
mmalsina@clinic.cat
+34932275600 ext. 7503
Dinara Smarkanova, MD
Contact
dsamarkanova@bst.cat
+34935573500 ext. 6563
Miguel Maria Alsina Casanova, MD
principal investigator · Hospital Clinic of Barcelona
Dinara Smarkanova, MD
study director · Banc de Sang i Teixits
Miguel Ramón Jiménez, MD
principal investigator · Hospital Sant Joan de Deu
Fátima Camba Longueira, MD
principal investigator · Hospital Vall d'Hebron
María José García Borau, MD
principal investigator · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Marta Ocaña Rico, MD
principal investigator · Germans Trias i Pujol Hospital
Mònica Domingo Puiggròs, MD
principal investigator · Hospital Parc Taulí

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion